CERo Therapeutics Holdings, Inc.

Equities

CERO

US71902K1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.39 ^USD	+1.46%		-2.11%	-87.36%

Apr. 02	CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 11	Top Premarket Decliners	MT

CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

April 02, 2024 at 07:07 am EDT

CERo Therapeutics Holdings, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 2.54 million compared to USD 0.667736 million a year ago.

Latest news about CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Top Premarket Decliners	Mar. 11	MT
Top Premarket Gainers	Mar. 08	MT
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients	Mar. 07	CI
CERo Therapeutics Holdings, Inc. announced that it expects to receive $25 million in funding from Arena Business Solutions Global SPC II, Ltd.	Feb. 22	CI
Top Premarket Decliners	Feb. 20	MT
Phoenix Biotech Acquisition Completes Merger With CERo Therapeutics	Feb. 15	MT
Phoenix Biotech Acquisition Corp. Appoints Brian Atwood as Chief Executive Officer	Feb. 15	CI
Phoenix Biotech Acquisition Corp. Announces Executive and Board Changes	Feb. 15	CI
Phoenix Biotech Acquisition Corp. Appoints Charles Carter as Chief Financial Officer	Feb. 15	CI
Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index	Feb. 13	CI
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	Feb. 13	CI
CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding	Feb. 13	CI
Phoenix Biotech Acquisition Corp. Sinks 15% in Premarket Activity After Plunging 42% in Wednesday's Regular Trading	Feb. 08	MT
Phoenix Biotech Acquisition Corp. announced that it expects to receive $2 million in funding from Keystone Capital Partners LLC	Feb. 04	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Phoenix Biotech Acquisition Corp. executed the letter of intent to acquire CERo Therapeutics, Inc. for $86.9 million.	23-06-04	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Phoenix Biotech Acquisition Corp. announced that it expects to receive $1.5 million in funding	22-12-15	CI
Phoenix Biotech Acquisition Corp. cancelled the acquisition of Intrinsic Medicine, Inc. from Phoenix Biotech Sponsor, LLC, Beryl Capital Management LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P. and others.	22-12-05	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Phoenix Biotech to Take Intrinsic Medicine Public in SPAC Deal	22-10-31	MT

Chart CERo Therapeutics Holdings, Inc.

Duration

Period

More charts

Company Profile

CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Companyâs proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the bodyâs full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CERO THERAPEUTICS HOLDINGS, INC.	-87.36%	20.17M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs